文献速递淋巴瘤

淋巴瘤治疗性疫苗接种的临床试验:连续肿瘤采样与单细胞分析

A clinical trial of therapeutic vaccination in lymphoma with serial tumor sampling and single-cell analysis.
PubMed 文献 · Blood Adv · 2024-01-01

这项1/2期原位疫苗接种试验在低级别淋巴瘤患者中联合瘤内TLR9激动剂、局部低剂量放疗和伊布替尼,不良事件以低级别为主,总缓解率50%含1例完全缓解,所有患者远处病灶均缩小;单细胞分析显示CD47降低、MHC II类表达升高、T细胞和NK细胞效应功能增强及免疫抑制减少与临床缓解相关。

要点

  • 低级别淋巴瘤原位疫苗接种联合TLR9激动剂、局部低剂量放疗和伊布替尼,不良事件以低级别为主。
  • 总缓解率50%,含1例完全缓解,所有患者远处未注射病灶均出现肿瘤缩小。
  • 单细胞分析显示肿瘤细胞CD47降低、MHC II类表达升高、T细胞和NK细胞效应功能增强及免疫抑制减少与临床缓解相关。

核心结论

  • 诱导免疫效应细胞和逆转负向调控因子对于产生有临床意义的肿瘤缓解均很重要。

研究设计与样本

  • 1/2期原位疫苗接种试验,纳入低级别淋巴瘤患者,联合瘤内TLR9激动剂、局部低剂量放疗和伊布替尼。
  • 试验注册号为NCT02927964。

主要发现

  • 不良事件以低级别为主。
  • 总缓解率为50%,包括1例完全缓解。
  • 所有患者均出现远处病灶肿瘤缩小。
  • 对注射和未注射肿瘤的连续细针穿刺进行单细胞分析,发现临床缓解相关因素包括肿瘤细胞CD47降低和MHC II类表达升高、T细胞和NK细胞效应功能增强、转化生长因子β和抑制性T调节1细胞介导的免疫抑制减少。
  • 局部注射部位变化更明显,但远处未注射部位的变化更常与临床缓解相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In situ vaccination (ISV) triggers an immune response to tumor-associated antigens at 1 tumor site, which can then tackle the disease throughout the body. Here, we report clinical and biological results of a phase 1/2 ISV trial in patients with low-grade lymphoma, combining an intratumoral toll-like receptor 9 (TLR9) agonist with local low-dose radiation and ibrutinib (an inhibitor of B- and T-cell kinases). Adverse events were predominately low grade. The overall response rate was 50%, including 1 complete response. All patients experienced tumor reduction at distant sites. Single-cell analyses of serial fine needle aspirates from injected and uninjected tumors revealed correlates of clinical response, such as lower CD47 and higher major histocompatibility complex class II expression on tumor cells, enhanced T-cell and natural killer cell effector function, and reduced immune suppression from transforming growth factor β and inhibitory T regulatory 1 cells. Although changes at the local injected site were more pronounced, changes at distant uninjected sites were more often associated with clinical responses. Functional immune response assays and tracking of T-cell receptor sequences provided evidence of treatment-induced tumor-specific T-cell responses. Induction of immune effectors and reversal of negative regulators were both important in producing clinically meaningful tumor responses. The trial was registered at www.clinicaltrials.gov as #NCT02927964.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Shree T, Haebe S, Czerwinski DK, et al. A clinical trial of therapeutic vaccination in lymphoma with serial tumor sampling and single-cell analysis. Blood Adv. 2024. PMID: 37939259. doi:10.1182/bloodadvances.2023011589

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。